Asthma

This month's OTC case studies focuses on asthma.

Asthma contributed most to the risk of high blood pressure and coronary heart disease.

Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older

Singulair is a leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma.

Agency hopes green light for complex drug device combination improves competition and access more affordable medications.

Nucala is an IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) for the add-on maintenance treatment of adult and pediatric patients with severe asthma and with an eosinophilic phenotype.

Study findings support the role of tezepelumab-ekko as a first-in-class treatment for a broad population of patients living with severe asthma, irrespective of biomarker levels.

Wixela Inhub is indicated for the treatment of asthma in patients 4 years of age and older and maintenance treatment of patients with chronic obstructive pulmonary disease.

Breo Ellipta is indicated for long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

Advair Diskus is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease.

The study enrolled 214 patients, with 105 randomized to a risankizumab injection every 4 weeks over a 24-week period, while 109 patients received a placebo.

Dupilumab is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Benralizumab (Fasenra) is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.

Evidence of a causal relationship between the onset of allergic disease and mental health was limited, suggesting that the observational associations found were due to confounding or other forms of bias.

Ten quiz questions to assess your knowledge on common symptoms and treatments for asthma.

The approval is based on data from a phase 3 placebo-controlled trial that evaluated the efficacy and safety of dupilumab combined with standard-of-care therapy in children with uncontrolled moderate-to-severe asthma.

PT0271 improved lung function and reduced the risk of exacerbations in individuals with asthma.

A new study explores why individuals who suffer most from the condition have the worse symptoms at night.

Study indicates that patients with asthma should continue taking their asthma medications during the COVID-19 pandemic.

Inspiratory muscle training was originally devised to be used by athletes and individuals with breathing problems such as chronic obstructive pulmonary disease, asthma, and bronchitis.

Severe persistent asthma is the worse type of asthma.

Both asthma and chronic obstructive pulmonary disease cause swelling in the airways that makes it difficult to breathe.

Include pediatric patients in demonstrations and discussions to improve outcomes.

The FDA also granted Breakthrough Therapy Designation to tezepelumab for patients with severe asthma without an eosinophilic phenotype in September 2018.

A 300 mg dose is currently available with a prescription.

Study indicates that teens and adults who use e-cigarettes have increased odds of developing asthma and having asthma attacks.

Patients who added dupilumab to standard of care saw a 65% reduction in the rate of severe asthma attacks over 1 year.

Pharmacists should counsel patients periodically to ensure correct usage for better disease and treatment management.

Blood eosinophil counts and FeNO levels are 2 key inflammatory biomarkers used by clinicians to inform treatment options and were defined as blood eosinophil count and FeNO.